Propanc Health Group Corp (OTCMKTS:PPCH) Trying To Stabilize

[[tagnumber 0]][[tagnumber 1]]The stock of Propanc Health Group Corp (OTCMKTS:PPCH) hasn’t had such of a bad year so far this year, compared to a lot of other OTC entities. With a lot of hesitation we have seen the ticker climb the charts.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]][[tagnumber 6]]PPCH[[tagnumber 7]] was traded as low as $0.00315 per share back in the beginning of March and it managed to gain a massive 3700% by the middle of last month. Since then, however, it has been struggling and has slowly descended down the charts, recording few green sessions.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The whole positive movements of [[tagnumber 6]]PPCH[[tagnumber 7]] is kind of strange, considering the fact that their balance sheet looks very humble compared to other biotech OTC entities. Here are just some of the numbers contained in the company’s report for the first quarter of the year.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 17]] [[tagnumber 18]]cash: $168 thousand[[tagnumber 19]] [[tagnumber 18]]current assets: $308 thousand[[tagnumber 19]] [[tagnumber 18]]current liabilities: $2.16 million[[tagnumber 19]] [[tagnumber 18]]revenues: $0[[tagnumber 19]] [[tagnumber 18]]net loss: $454 thousand[[tagnumber 19]] [[tagnumber 28]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]These digits certainly seem quite depressing, especially when you consider the fact that [[tagnumber 6]]PPCH[[tagnumber 7]] has a long way until it can produce any potential revenue–generating product. The biggest problem is, as always, dilution. As you can clearly see, [[tagnumber 6]]PPCH[[tagnumber 7]] doesn’t have the means to continue with its research so it gets toxic funding.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Looking at the Q1 report you can see that a total of $1.13 million of the company’s current liabilities consist of convertible notes. Some later filings reveal an even grimmer situation. In the seven months before May 15, 2015 the company issued a total of 244 million shares of its common stock, raising the outstanding share count to 355 million.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Considering the fact that [[tagnumber 6]]PPCH[[tagnumber 7]] is still in the pilot animal studies phase there would be years before the company can eventually get an FDA approval for their cancer treatment. Still, yesterday’s press release seems to have brought investors some hope and we saw the ticker climb 11.97% on a daily dollar volume of $664 thousand.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Bearing in mind the tragic balance sheet, the toxic debt and the possibility for massive dilution in the near and not–so–near future is absolutely crucial when approaching [[tagnumber 6]]PPCH.[[tagnumber 7]][[tagnumber 2]]